← Eichor
Condition: Tyrosine Kinase Inhibitor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tyrosine Kinase Inhibitor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Phase 2 · 1 location(s) · Qingdao Central Hospital · NCT04974866A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib
Phase 3 · 91 location(s) · BeOne Medicines · NCT07277231Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (G
Phase 2 · 13 location(s) · Centre Leon Berard · NCT05009927The TASTY-training Study
NA · 11 location(s) · University Medical Center Groningen · NCT07258589An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Phase N/A · 1 location(s) · Blueprint Medicines Corporation · NCT07264959Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06014827A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1 · 21 location(s) · Nuvalent Inc. · NCT06521554A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Phase 2 · 3 location(s) · Yale University · NCT02491099Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 · 1 location(s) · Queen Mary Hospital, Hong Kong · NCT06643416A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Phase 2 · 1 location(s) · Korean Society of Hematology · NCT06368414Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2 · 3 location(s) · Anwaar Saeed · NCT06698250XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Phase 3 · 68 location(s) · EyePoint Pharmaceuticals, Inc. · NCT07449923ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Phase 1 · 4 location(s) · Enliven Therapeutics · NCT06787144A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Le
Phase 2 · 11 location(s) · Curis, Inc. · NCT07271667Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutation
Phase N/A · 2 location(s) · University of Colorado, Denver · NCT03958565Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Phase 3 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05852990Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant
Phase 1/Phase 2 · 1 location(s) · State University of New York at Buffalo · NCT06222593Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic
NA · 1 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT05130138Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
Phase 4 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07092202A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-smal
Phase 3 · 29 location(s) · Nuvation Bio Inc. · NCT06564324A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Out
Phase N/A · 17 location(s) · Novartis Pharmaceuticals · NCT07091019Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
Phase 2 · 1 location(s) · Jinling Hospital, China · NCT07571551Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemi
Phase N/A · 8 location(s) · BeiGene · NCT05640102Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During o
Phase 1/Phase 2 · 30 location(s) · Merck Sharp & Dohme LLC · NCT07049926ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07157969Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
Phase N/A · 2 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06940102Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.